Abcuro Secures $200M Series C to Advance Ulviprubart for IBM
Slice of Healthcare Team
Feb 19, 2025
Key Highlights
- Abcuro raises $200M in Series C funding led by New Enterprise Associates (NEA) with participation from Foresite Capital and existing investors.
- Funding supports Phase 2/3 MUSCLE trial for ulviprubart (ABC008) in inclusion body myositis (IBM).
- Ulviprubart is a first-in-class monoclonal antibody targeting KLRG1 to selectively deplete cytotoxic T cells.
- Initial data expected in H1 2026, with a potential Biologics License Application (BLA) filing upon positive results.
- Funds will also support manufacturing expansion and pre-commercial activities.
Source: Business Wire
Notable Quotes
“ Continued support from all of our investors in this latest financing round validates our vision for the potential that ulviprubart may have as a novel treatment for progressive and devastating diseases mediated by highly cytotoxic T cells, including Inclusion Body Myositis. ”
— Alex Martin, Chief Executive Officer at Abcuro
“ Abcuro represents an exciting opportunity with its lead candidate, ulviprubart, a potential first-in-class therapy that could make a big impact to the treatment paradigm of IBM, an indication with a significant unmet clinical need. ”
— Michele Park, PhD, Partner at NEA
Why This Matters
no disease-modifying treatments currently available FDA and EMA granting orphan drug designation major step forward in developing a potential first-in-class therapy positions Abcuro for future commercialization
